Posts tagged oncology
Zymeworks platforms validated by pharma partnerships

Zymeworks’ (NYSE, TSX:ZYME) marquee partnerships with Merck, Eli Lilly, Celgene, GlaxoSmithKline and Daiichi-Sankyo provide validation for its next-generation oncology platforms, with the potential for $4.1-billion in milestone payments.

Read More
In conversation with Lloyd Segal of Repare

As president and CEO of upstart Repare Therapeutics, Lloyd Segal was instrumental is arranging the initial funding to create Repare while he served as an entrepreneur-in-residence at Versant Ventures, a leading healthcare investment firm with a hands-on approach to company building. Repare is developing precision oncology drugs that target specific vulnerabilities of tumor cells...

Read More
Contextual Genomics detecting genetic mutations in cancer

Closely-held Contextual Genomics is giving oncologists a leg up to enhance cancer care with its new Find-It molecular test to detect genetic mutations in cancer patients.

Read More
In conversation with Chiara Russo

As a specialty pharmaceuticals analyst with Cantor Fitzgerald for the past 2 1/2 years, Chiara Russo covers developmental-stage companies that are on the cusp of changing the medical landscape as we know it. A philosophy major with an MBA from the Olin School of Business at Babson College, Ms. Russo was a R&D innovation consultant for Cubist Pharmaceuticals before becoming a sell-side equity research analyst. On the Street, she has been a research associate at ThinkEquity and VP and specialty pharmaceuticals analyst at Janney Montgomery Scott. In this interview with, Ms. Russo discusses industry trends and some of the stocks she likes.

Read More
In conversation with Mohit Trikha

As chief scientific officer, EVP and head of closely held Triphase Accelerator, Mohit Trikha has parlayed a successful 20-year track record in oncology drug development into a home run, selling Triphase’s first asset, a proteasome inhibitor known as marizomib, to Celgene (NASDAQ:CELG). Prior to joining Triphase, Dr. Trikha was associate VP of clinical development at Ambit Biosciences; director of BioOncology and early development at Genentech; and assistant director of oncology research at J&J’s Centocor. 

Read More
Immunovaccine targets three clinical milestones

Immunovaccine (OTCQX:IMMVF; TSX:IMV) expects to report three clinical milestones for its killer T cell activation vaccine platform, DepoVax, in ovarian and HPV cancers in the next 12 months.

Read More
Merus Labs moving up the value chain

After an 18-month company transformation under new CEO, Barry Fishman, Merus Labs International (NASDAQ:MSLI; TSX:MSL) is now ready to in-license new pharmaceutical products, in addition to optimizing existing products and continuing to acquire legacy products that are no longer strategic for major pharmaceutical companies.

“Since the fall of 2014, we’ve strengthened the management team and European platform, acquired additional products and improved the balance sheet and cash flow,” Mr. Fishman says in an interview with

Read More
ARIAD hopes to launch second oncology drug in early 2017

ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small cell lung cancer.

At the end of 2012, the company launched Iclusig (ponatinib) to treat patients with several genetic types of chronic myeloid leukemia.

“As an orphan oncology company, we address discrete populations of patients that are genetically defined,” Tim Clackson, president of R&D and CSO, says in an interview with

Read More
In conversation with Kevin Smith

As the newly appointed chief commercial officer of closely-held Sensium Healthcare, a pioneer in wireless monitoring of patient vital signs, Kevin Smith is in charge of developing and executing the company’s global commercial strategy. He also controls partnering with U.S. hospitals and medical universities and building clinical evidence for SensiumVitals, the first early warning detection device to be introduced by Sensium Healthcare. Mr. Smith has almost 20 years in the medical device industry, working on developing and accelerating domestic and international sales and product launches for numerous medical companies. Prior to joining Sensium, Mr. Smith was a VP of sales and marketing for Teleflex Medical, which manufactures and sells Class 2 and Class 3 devices into the catheter lab and cardiovascular operating room environments. In this interview with BioTuesdays, Mr. Smith discusses the SensiumVitals patch, which has received regulatory approval in the U.S. and Europe, and its competitive advantages.

Read More